title: Individualization of antiretroviral therapy--pharmacogenomic aspect.
abstract: Combination therapy with three drug regimens for human immunodeficiency virus (HIV) infection significantly suppresses the viral replication. However, this therapeutic impact is restricted by adverse drug events and response in terms of short and long term efficacy. There are multiple factors involved in different responses to antiretrovirals (ARVs) such as age, body weight, disease status, diet and heredity. Pharmacogenomics deals with individual genetic make-up and its role in drug efficacy and toxicity. In depth genetic research has provided evidence to predict the risk of developing certain toxicities for which personalized screening and surveillance protocols may be developed to prevent side effects. Here we describe the use of pharmacogenomics for optimal use of HAART (highly active antiretroviral therapy).
authors.forename: Bhavik
authors.initials: B
authors.lastname: Dalal
authors.affiliation: Department of Transfusion Transmitted Disease, National Institute of Immunohaematology (ICMR), Mumbai, India.
authors.forename: Aruna
authors.initials: A
authors.lastname: Shankarkumar
authors.forename: K
authors.initials: K
authors.lastname: Ghosh
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010597:Pharmacogenetics
chemical_list: D019380:Anti-HIV Agents
references.citation: J Infect Dis. 2008 Sep 15;198(6):864-7
references.pmid: 18684101
references.citation: Ther Drug Monit. 2012 Apr;34(2):153-9
references.pmid: 22354160
references.citation: Lancet. 2002 Mar 30;359(9312):1121-2
references.pmid: 11943262
references.citation: Drugs. 1996 May;51(5):846-64
references.pmid: 8861550
references.citation: Rev Med Virol. 2002 May-Jun;12(3):179-93
references.pmid: 11987143
references.citation: J Antimicrob Chemother. 2008 Jan;61(1):200-5
references.pmid: 17999977
references.citation: Drugs. 2003;63(23):2555-74
references.pmid: 14636077
references.citation: Antiviral Res. 2010 Jan;85(1):190-200
references.pmid: 19744523
references.citation: AIDS. 2014 May 15;28(8):1143-53
references.pmid: 25028911
references.citation: AIDS. 2001 Jan 5;15(1):71-5
references.pmid: 11192870
references.citation: J Infect Dis. 2005 Oct 15;192(8):1381-6
references.pmid: 16170755
references.citation: Viruses. 2010 Apr;2(4):880-99
references.pmid: 21994659
references.citation: Drug Metab Dispos. 1999 Dec;27(12):1488-95
references.pmid: 10570031
references.citation: J Antimicrob Chemother. 2010 Aug;65(8):1567-9
references.pmid: 20534626
references.citation: Pharmacol Rev. 2011 Jun;63(2):437-59
references.pmid: 21436344
references.citation: J Infect Dis. 2010 Sep 1;202(5):717-22
references.pmid: 20662624
references.citation: Antimicrob Agents Chemother. 2003 Jan;47(1):238-43
references.pmid: 12499197
references.citation: AIDS. 2000 Dec 1;14(17):2788-90
references.pmid: 11125899
references.citation: Pharmacogenet Genomics. 2009 Feb;19(2):139-46
references.pmid: 19104471
references.citation: World J Cardiol. 2010 Mar 26;2(3):53-7
references.pmid: 21160756
references.citation: Antimicrob Agents Chemother. 2011 Nov;55(11):5314-24
references.pmid: 21896912
references.citation: AIDS Patient Care STDS. 2007 Aug;21(8):603-4
references.pmid: 17902243
references.citation: Pharmacogenomics. 2011 Jun;12(6):809-14
references.pmid: 21510768
references.citation: Eur J Med Res. 2003 Dec 9;8(12):531-4
references.pmid: 14711599
references.citation: J Antimicrob Chemother. 2011 Apr;66(4):802-12
references.pmid: 21393174
references.citation: AIDS. 2004 Dec 3;18(18):2391-400
references.pmid: 15622315
references.citation: Clin Infect Dis. 2009 Jun 1;48(11):e108-16
references.pmid: 19400747
references.citation: AIDS. 2005 Jan 3;19(1):97-9
references.pmid: 15627041
references.citation: Expert Opin Drug Saf. 2002 May;1(1):5-17
references.pmid: 12904155
references.citation: AIDS. 2008 Feb 19;22(4):540-1
references.pmid: 18301070
references.citation: J Biol Chem. 2011 Sep 23;286(38):33409-21
references.pmid: 21775441
references.citation: Curr Opin HIV AIDS. 2009 Mar;4(2):82-7
references.pmid: 19339945
references.citation: Clin Infect Dis. 2006 Feb 1;42(3):401-7
references.pmid: 16392089
references.citation: Pharmacogenomics. 2009 Apr;10(4):623-37
references.pmid: 19374518
references.citation: J Pharmacol Exp Ther. 1996 Apr;277(1):423-31
references.pmid: 8613951
references.citation: Clin Infect Dis. 2006 Sep 15;43(6):783-6
references.pmid: 16912957
references.citation: J Infect Dis. 2006 Dec 1;194(11):1481-91
references.pmid: 17083032
references.citation: Clin Infect Dis. 2006 Sep 15;43(6):779-82
references.pmid: 16912956
references.citation: Pharmacogenet Genomics. 2006 Mar;16(3):191-8
references.pmid: 16495778
references.citation: Lancet Infect Dis. 2011 May;11(5):394-407
references.pmid: 21429803
references.citation: Eur J Med Res. 2009 Sep 1;14(9):369-77
references.pmid: 19748856
references.citation: Eur J Haematol. 2003 Jun;70(6):410-2
references.pmid: 12756025
references.citation: Pharmacogenet Genomics. 2007 Sep;17(9):755-64
references.pmid: 17700364
references.citation: Clin Chim Acta. 2011 Jul 15;412(15-16):1382-4
references.pmid: 21514285
references.citation: J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9
references.pmid: 16791115
references.citation: Mol Pharmacol. 2007 Feb;71(2):619-27
references.pmid: 17110501
references.citation: Pharmacogenet Genomics. 2012 Dec;22(12):891-4
references.pmid: 22960662
references.citation: Antimicrob Agents Chemother. 2010 Nov;54(11):4619-25
references.pmid: 20823282
references.citation: Hepatology. 2002 Jan;35(1):182-9
references.pmid: 11786975
references.citation: Clin Infect Dis. 2005 May 1;40(9):1358-61
references.pmid: 15825040
references.citation: Clin Pharmacol Ther. 2009 Jun;85(6):623-7
references.pmid: 19279563
references.citation: Clin Infect Dis. 2004 Feb 1;38(3):430-2
references.pmid: 14727217
references.citation: Pharmacotherapy. 2004 Feb;24(2):198-211
references.pmid: 14998221
references.citation: Br J Clin Pharmacol. 2011 May;71(5):659-71
references.pmid: 21480946
references.citation: J Korean Med Sci. 2010 Oct;25(10):1427-30
references.pmid: 20890421
references.citation: J Pharmacol Exp Ther. 2008 Jun;325(3):859-68
references.pmid: 18364470
references.citation: Eur J Hum Genet. 2001 Oct;9(10):794-6
references.pmid: 11781692
references.citation: Pharmacogenet Genomics. 2005 Jan;15(1):1-5
references.pmid: 15864119
references.citation: Clin Infect Dis. 2006 Jan 15;42(2):291-5
references.pmid: 16355344
references.citation: Pharmacogenet Genomics. 2010 Dec;20(12):759-65
references.pmid: 21217360
references.citation: Int J STD AIDS. 2009 Mar;20(3):145-51
references.pmid: 19255258
references.citation: J Antimicrob Chemother. 2008 Apr;61(4):914-8
references.pmid: 18281305
references.citation: Curr Cardiol Rev. 2008 Aug;4(3):203-18
references.pmid: 19936197
references.citation: Indian J Med Res. 2010 Oct;132:386-9
references.pmid: 20966515
references.citation: Lancet. 2002 Jan 5;359(9300):30-6
references.pmid: 11809184
references.citation: J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):74-8
references.pmid: 17971715
references.citation: AIDS. 2011 Jun 19;25(10):1271-80
references.pmid: 21505298
references.citation: AIDS. 2001 May 25;15(8):1019-23
references.pmid: 11399984
references.citation: Clin Infect Dis. 2008 Nov 1;47(9):1222-5
references.pmid: 18831695
references.citation: J Clin Pharmacol. 2009 Sep;49(9):1079-90
references.pmid: 19628728
references.citation: AIDS. 2010 Mar 27;24(6):885-90
references.pmid: 19952712
references.citation: Lancet. 2002 Mar 2;359(9308):727-32
references.pmid: 11888582
references.citation: J Pharmacol Pharmacother. 2011 Apr;2(2):114-5
references.pmid: 21772773
references.citation: Pharmgenomics Pers Med. 2012;5:1-17
references.pmid: 23226059
references.citation: AIDS. 1997;11 Suppl A:S157-64
references.pmid: 9451980
references.citation: HIV Clin Trials. 2010 Mar-Apr;11(2):69-79
references.pmid: 20542844
references.citation: N Engl J Med. 2006 Jan 19;354(3):251-60
references.pmid: 16421366
references.citation: Pharmacogenomics. 2010 Jan;11(1):23-31
references.pmid: 20017669
references.citation: Pharmacogenet Genomics. 2005 Dec;15(12):861-73
references.pmid: 16272958
references.citation: Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6
references.pmid: 15194512
references.citation: Science. 2000 Jan 28;287(5453):646-50
references.pmid: 10649997
references.citation: J Antimicrob Chemother. 2011 Jun;66(6):1332-9
references.pmid: 21441248
references.citation: J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303
references.pmid: 18398970
references.citation: Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12128-32
references.pmid: 9342374
references.citation: AIDS. 2007 Jan 2;21(1):41-6
references.pmid: 17148966
references.citation: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37
references.pmid: 18333863
references.citation: PLoS Biol. 2005 Nov;3(11):e378
references.pmid: 16248677
references.citation: Pharmacogenetics. 1998 Aug;8(4):283-9
references.pmid: 9731714
references.citation: AIDS. 2001 Nov 23;15(17):2259-66
references.pmid: 11698699
references.citation: AIDS. 2006 Aug 1;20(12):1621-6
references.pmid: 16868443